The insulin-like growth factor 1 receptor in cancer: Old focus, new future

被引：144

作者：

Hartog, Hermien

Wesseling, Jelle

Boezen, H. Marike

van der Graaf, Winette T. A.

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Univ Groningen, Med Ctr, Dept Oncol, Groningen, Netherlands

[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands

[4] Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 13期

关键词：

insulin-like growth factor 1 receptor; insulin receptor; hybrid receptor; tyrosine kinase inhibitors; targeted therapy; growth factor receptor; antibody; cancer;

D O I：

10.1016/j.ejca.2007.05.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of insulin-like growth factor I receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases 1 and 11 clinical trials. interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1895 / 1904

页数：10

共 106 条

[81] Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase [J].

Sarma, P. K. S. ;

Tandon, Ruchi ;

Gupta, Praful ;

Dastidar, Sunanda G. ;

Ray, Abhijit ;

Das, Biswajit ;

Cliffe, Ian A. .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (01) :25-35

[82]

Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO

[83]

2-F

[84] Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor [J].

Schnitzer, T. ;

Kuenkele, K. -P. ;

Rebers, F. ;

Van Vugt, M. ;

Klein, C. ;

Lanzendoerfer, M. ;

Mundigl, O. ;

Parren, P. W. H. I. ;

van de Winkel, J. G. J. ;

Schumacher, R. .

EJC SUPPLEMENTS, 2006, 4 (12) :66-67

[85] Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism [J].

Sciacca, L ;

Costantino, A ;

Pandini, G ;

Mineo, R ;

Frasca, F ;

Scalia, P ;

Sbraccia, P ;

Goldfine, ID ;

Vigneri, R ;

Belfiore, A .

ONCOGENE, 1999, 18 (15) :2471-2479

[86] Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors [J].

Scotlandi, K ;

Manara, MC ;

Nicoletti, G ;

Lollini, PL ;

Lukas, S ;

Benini, S ;

Croci, S ;

Perdichizzi, S ;

Zamberi, D ;

Serra, M ;

García-Echeverría, C ;

Hofmann, F ;

Picci, P .

CANCER RESEARCH, 2005, 65 (09) :3868-3876

[87] Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells [J].

Scotlandi, K ;

Avnet, S ;

Benini, S ;

Manara, MC ;

Serra, M ;

Cerisano, V ;

Perdichizzi, S ;

Lollini, PL ;

De Giovanni, C ;

Landuzzi, L ;

Picci, P .

INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :11-16

[88] Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells [J].

Scotlandi, K ;

Maini, C ;

Manara, MC ;

Benini, S ;

Serra, M ;

Cerisano, V ;

Strammiello, R ;

Baldini, N ;

Lollini, PL ;

Nanni, P ;

Nicoletti, G ;

Picci, P .

CANCER GENE THERAPY, 2002, 9 (03) :296-307

[89]

SEKYIOTU A, 1995, CANCER RES, V55, P129

[90] SIMIAN VIRUS-40 LARGE TUMOR-ANTIGEN IS UNABLE TO TRANSFORM MOUSE EMBRYONIC FIBROBLASTS LACKING TYPE-1 INSULIN-LIKE GROWTH-FACTOR RECEPTOR [J].

SELL, C ;

RUBINI, M ;

RUBIN, R ;

LIU, JP ;

EFSTRATIADIS, A ;

BASERGA, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11217-11221

← 2 3 4 5 6 7 8 9 10 11 →